Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 19/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 18/20 | 0.70 |
| ▸ | ITGB7 | P26010 | 15/20 | 0.70 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819408 | 0.92 | ITGA4 (0.68) | ITGA4ITGB1ITGB7 | |
| SCHEMBL13819122 | 0.91 | ITGA4 (0.70) | ITGA4ITGB1ITGB7ITGB3ITGAV | |
| SCHEMBL4811214 | 0.91 | ITGA4 (0.72) | ITGA4ITGB1ITGB7 | |
| SCHEMBL4818557 | 0.90 | ITGA4 (0.71) | ITGA4ITGB1ITGB7 | |
| SCHEMBL13819401 | 0.89 | ITGA4 (0.69) | ITGA4ITGB1ITGB7 | |
| SCHEMBL13819221 | 0.89 | ITGA4 (0.90) | ITGA4ITGB1ITGB7 | |
| SCHEMBL4821770 | 0.87 | ITGA4 (0.74) | ITGA4ITGB1ITGB7 | |
| SCHEMBL10329628 | 0.87 | ITGA4 (0.66) | ITGA4ITGB1ITGB7 | |
| SCHEMBL13819224 | 0.86 | ITGA4 (0.75) | ITGA4ITGB1ITGB7 | |
| SCHEMBL13819429 | 0.86 | ITGA4 (0.64) | ITGA4ITGB1ITGB7ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309561-B2 | N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation | AJINOMOTO CO., INC. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8309561-B2 | N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation | AJINOMOTO CO., INC. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7345049-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-7345049-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108634-A1 | NOVEL PHENYLALANINE DERIVATIVES | ITGB4, ITGA4, ITGAV | ITGA4 2/4885ITGB1 10/4885ITGB7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.